Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease - PubMed (original) (raw)

Review

. 2019 Jun 24:2019:7659509.

doi: 10.1155/2019/7659509. eCollection 2019.

Affiliations

Review

Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease

Caihua Wang et al. Mediators Inflamm. 2019.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a major health threat around the world and is characterized by dysbiosis. Primary bile acids are synthesized in the liver and converted into secondary bile acids by gut microbiota. Recent studies support the role of bile acids in modulating dysbiosis and NAFLD, while the mechanisms are not well elucidated. Dysbiosis may alter the size and the composition of the bile acid pool, resulting in reduced signaling of bile acid receptors such as farnesoid X receptor (FXR) and Takeda G protein-coupled receptor 5 (TGR5). These receptors are essential in lipid and glucose metabolism, and impaired bile acid signaling may cause NAFLD. Bile acids also reciprocally regulate the gut microbiota directly via antibacterial activity and indirectly via FXR. Therefore, bile acid signaling is closely linked to dysbiosis and NAFLD. During the past decade, stimulation of bile acid receptors with their agonists has been extensively explored for the treatment of NAFLD in both animal models and clinical trials. Early evidence has suggested the potential of bile acid receptor agonists in NAFLD management, but their long-term safety and effectiveness need further clarification.

PubMed Disclaimer

References

    1. Younossi Z. M., Koenig A. B., Abdelatif D., Fazel Y., Henry L., Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi: 10.1002/hep.28431. - DOI - PubMed
    1. Brunt E. M., Wong V. W. S., Nobili V., et al. Nonalcoholic fatty liver disease. Nature Reviews Disease Primers. 2015;1(1, article 15080) doi: 10.1038/nrdp.2015.80. - DOI - PubMed
    1. Pan J. J., Fallon M. B. Gender and racial differences in nonalcoholic fatty liver disease. World Journal of Hepatology. 2014;6(5):274–283. doi: 10.4254/wjh.v6.i5.274. - DOI - PMC - PubMed
    1. Spengler E. K., Loomba R. Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mayo Clinic Proceedings. 2015;90(9):1233–1246. doi: 10.1016/j.mayocp.2015.06.013. - DOI - PMC - PubMed
    1. Adams L. A., Anstee Q. M., Tilg H., Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138–1153. doi: 10.1136/gutjnl-2017-313884. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources